Literature DB >> 26869157

Reply to 'Comment on: Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizmab'.

T D Papakostas1, D Vavvas1, D Eliott1, L A Kim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26869157      PMCID： PMC4869148          DOI： 10.1038/eye.2016.6

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  6 in total

1.  Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.

Authors:  T D Papakostas; L Lim; T van Zyl; J B Miller; B S Modjtahedi; C M Andreoli; D Wu; L H Young; I K Kim; D G Vavvas; D D Esmaili; D Husain; D Eliott; L A Kim
Journal:  Eye (Lond)       Date:  2015-10-09       Impact factor: 3.775

2.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2010-04-09       Impact factor: 12.079

3.  Comment on: 'Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab'.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

4.  Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography.

Authors:  Robert B Bhisitkul; Peter A Campochiaro; Howard Shapiro; Roman G Rubio
Journal:  Ophthalmology       Date:  2013-02-14       Impact factor: 12.079

5.  Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

Authors:  Benjamin Bakall; James C Folk; H Culver Boldt; Elliott H Sohn; Edwin M Stone; Stephen R Russell; Vinit B Mahajan
Journal:  Am J Ophthalmol       Date:  2013-05-22       Impact factor: 5.258

6.  Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.

Authors:  Yoshihiro Yonekawa; Christopher Andreoli; John B Miller; John I Loewenstein; Lucia Sobrin; Dean Eliott; Demetrios G Vavvas; Joan W Miller; Ivana K Kim
Journal:  Am J Ophthalmol       Date:  2013-05-10       Impact factor: 5.258
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.